UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Strategy Inc
MSTR
|
+$1.21B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$855M |
| 3 |
Microsoft
MSFT
|
+$810M |
| 4 |
Advanced Micro Devices
AMD
|
+$805M |
| 5 |
Boeing
BA
|
+$739M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$561M |
| 2 |
Amneal Pharmaceuticals
AMRX
|
+$169M |
| 3 |
Eli Lilly
LLY
|
+$161M |
| 4 |
Unity
U
|
+$158M |
| 5 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$127M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.49% |
| 2 | Financials | 9.06% |
| 3 | Consumer Discretionary | 7.01% |
| 4 | Healthcare | 6.25% |
| 5 | Industrials | 6.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
6326
Full House Resorts
FLL
$89M
| $240K | ﹤0.01% |
58,727
+37,526
| +177% | +$177K |
|
6327
American Well
AMWL
$230M
| $239K | ﹤0.01% |
32,993
+30,767
| +1,382% | +$279K |
|
6328
RH Tactical Outlook ETF
RHTX
$8.25M
| $239K | ﹤0.01% |
14,724
+7,189
| +95% | +$119K |
|
6329
PUT
Vertiv
VRT
$105B
| $239K | ﹤0.01% |
2,100
-77,000
| -97% | -$9.14M |
|
6330
Xilio Therapeutics
XLO
$60.3M
| $238K | ﹤0.01% |
17,814
+16,690
| +1,485% | +$230K |
|
|
QVCGA
6331
DELISTED
QVC Group Inc Series A
QVCGA
| $238K | ﹤0.01% |
14,411
+5,145
| +56% | +$120K |
|
6332
NRC Health Common Stock
NRC
$450M
| $238K | ﹤0.01% |
13,476
+4,020
| +43% | +$76.2K |
|
|
TSE
6333
DELISTED
Trinseo
TSE
| $238K | ﹤0.01% |
46,599
+40,843
| +710% | +$202K |
|
6334
Compass Therapeutics
CMPX
$387M
| $237K | ﹤0.01% |
163,656
+98,256
| +150% | +$163K |
|
6335
FT Vest US Equity Moderate Buffer ETF February
GFEB
$382M
| $237K | ﹤0.01% |
6,347
-4,813
| -43% | -$178K |
|
|
RAPT
6336
DELISTED
RAPT Therapeutics
RAPT
| $236K | ﹤0.01% |
18,709
+15,103
| +419% | +$192K |
|
|
NAGE
6337
Niagen Bioscience
NAGE
$247M
| $236K | ﹤0.01% |
44,473
-14,416
| -24% | -$78.9K |
|
6338
Roundhill Sports Betting & iGaming ETF
BETZ
$49.6M
| $235K | ﹤0.01% |
12,411
+11,716
| +1,686% | +$226K |
|
6339
AN2 Therapeutics
ANTX
$214M
| $235K | ﹤0.01% |
+170,292
| New | +$207K |
|
6340
Fidelity Small-Mid Multifactor ETF
FSMD
$2.59B
| $235K | ﹤0.01% |
5,699
+4,269
| +299% | +$181K |
|
6341
Fidelity Enhanced Large Cap Growth ETF
FELG
$5.75B
| $234K | ﹤0.01% |
6,630
-1,829
| -22% | -$63.4K |
|
6342
Day Hagan/Ned Davis Research Smart Sector ETF
SSUS
$585M
| $234K | ﹤0.01% |
5,555
-2,375
| -30% | -$101K |
|
6343
Arcos Dorados Holdings
ARCO
$1.74B
| $233K | ﹤0.01% |
32,006
+10,677
| +50% | +$91.5K |
|
|
VBFC
6344
DELISTED
Village Bank and Trust Financial Corp.
VBFC
| $233K | ﹤0.01% |
2,997
-100
| -3% | -$7.68K |
|
6345
Fidelity MSCI Industrials Index ETF
FIDU
$2.39B
| $232K | ﹤0.01% |
3,302
+35
| +1% | +$2.58K |
|
|
MRSN
6346
DELISTED
Mersana Therapeutics
MRSN
| $232K | ﹤0.01% |
6,491
-12,450
| -66% | -$644K |
|
6347
Betterware México
BWMX
$623M
| $231K | ﹤0.01% |
20,642
+19,289
| +1,426% | +$236K |
|
|
ZENA
6348
ZenaTech Inc
ZENA
$147M
| $231K | ﹤0.01% |
+30,003
| New | +$131K |
|
6349
Mid Penn Bancorp
MPB
$952M
| $231K | ﹤0.01% |
7,994
+832
| +12% | +$25.7K |
|
6350
Envela
ELA
$446M
| $230K | ﹤0.01% |
32,081
+30,043
| +1,474% | +$187K |
|
Similar funds
UBS Group's Q4 2024 Portfolio in Review
As of Q4 2024, UBS Group held 10,816 positions worth $541B, up 18% from $459B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
UBS Group deployed $80.6B of net new capital in Q4 2024, opening 1,382 new positions and adding to 6,044 existing holdings. Its largest new stake was Primo Brands: 1,234,826 shares worth $38M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was UnitedHealth, an estimated $561M trimmed.
- UBS Group's largest Q4 2024 buy was Primo Brands: 1,234,826 shares worth $38M.
- UBS Group added most to Strategy Inc in Q4 2024, an estimated $1.21B increase.
- UBS Group's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $561M.
- UBS Group fully exited CATALENT, INC. in Q4 2024, selling an estimated $86M.
- UBS Group's ten largest holdings make up 16% of its $541B portfolio in Q4 2024.
- UBS Group opened 1,382 new positions and closed 943 in Q4 2024.
- UBS Group's portfolio value rose 18% quarter-over-quarter to $541B.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.